← back to rankingHIMS · Hims & Hers Health, Inc.
Medical - Equipment & Services · mkt cap $6.1B · calls: Q1 FY2026 vs Q4 FY2025
62.0 conviction · conf-adj 62
conf 2/10 partial
enthusiasm:27.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:5 · business_impact:8 · disruption:0 · commitment:6 · confirmation:3
Enthusiasm latest 9 / prev 7 (rising)
The AI thesis rose sharply in Q1 FY2026: management moved from broad AI/data ambitions to named products, a CTO-led AI narrative, Labs AI, provider copilots, planned weight-loss agents, and a proprietary clinician-verified training loop. Credibility is moderate: HIMS has a plausible data advantage from closed-loop care and high customer touchpoints, but quantified AI business impact remains thin, with only a prior engagement metric tied directly to AI-enabled/proactive messaging.
GROUNDED NEXT-FY IMPACT vs CONSENSUS
Grounded on actual base — revenue $2.3B · net income $0.1B · net margin 5.5% · diluted EPS 0.51
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: medium · confidence: 2/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|
Proactive messaging increased weight logging frequency
engagement · soft | more than a 50% increase | Engagement metric only. No disclosed base ties weight-logging frequency to a revenue line (no per-log monetization, affected subscriber base, retention delta, or ARPU figure appears anywhere in the inputs). 50% × (no anchorable $ base) -> cannot convert to revenue or net income; @ current net margin 5.4678% still yields no EPS arithmetic without revenue. Soft. | | |
AI weight loss companion to support customers and prompt clinicians
engagement · soft | no quantified financial figure | No $ amount, subscriber base, take-rate, retention, or utilization conversion disclosed; next-FY revenue and EPS impact cannot be calculated. | | |
AI may reduce organizational and operational costs
cost · soft | no quantified saving; benefits could start in 2027 | No cost-saving $ amount or cost base disclosed. Timing points to 2027, not next fiscal year 2026, so no next-FY saving can be calculated. If a saving were disclosed, after-tax saving would use 21% tax rate. | 0 | |
AI layer for precision treatments and lifestyle adjustments
other · soft | no quantified financial figure | No $ amount, price uplift, conversion lift, retention lift, or cost-saving base disclosed; revenue and EPS impact cannot be calculated. | | |
Assumptions: Next fiscal year is FY2026. Default incremental net margin 5.4678% (= current net margin) and 21% tax rate were prepared but never used — no anchored $ figure to flow through. No phasing applied because no quantified revenue or cost base exists. Weight-logging frequency was treated as an engagement KPI, not directly mappable to revenue without a disclosed segment base or retention/conversion coefficient. All four forward-looking statements are unquantified and excluded from math.
Top line: No hard topline impact is calculable. The only quantified metric is the >50% weight-logging frequency lift — an engagement signal, not revenue. Nothing in the inputs converts logging frequency to dollars (no per-user revenue delta, retention uplift, or subscriber-conversion rate disclosed), so no topline % can be honestly computed against the $2.348B base. Consensus already models 2026 revenue +23% to $2.888B; whether AI engagement contributes is not separable.
Bottom line: No hard EPS impact is calculable. No quantified cost, headcount, or productivity saving was given — management only says efficiency benefits 'could start to emerge in 2027' and AI has the 'potential to reduce' costs. With current net income $128.4M and diluted EPS $0.51 (profitable, so an EPS-uplift % would be meaningful if anchored), there is still no figure to flow through (1-21%) tax. est_eps_uplift_pct = null.
[impact n/m (all claims soft/unanchored)] No adopter-side AI figure can be sized, so there is no AI-specific number to test against consensus. Consensus trajectory: revenue ~$2.349B(25) -> $2.888B(26, +23%) -> ~$3.441B(27, +19%); EPS ~$0.46 -> -$0.043 (2026 loss) -> ~$0.51 (2027 recovery). The 2027 EPS rebound roughly coincides with the window where management says AI efficiency 'could start to emerge,' so any benefit is plausibly already inside the 2027 recovery rather than incremental to it — but with the AI impact unquantified this is an inference, not a measured gap.
MODEL CONSENSUS (impact)
partial
Both agree all claims are soft/unquantifiable; consensus keeps X's itemization, Y's 2027-timing insight, and the lower confidence.
Conflicts reconciled
- math: X=4 itemized claims vs Y=1 -> used X's fuller per-claim breakdown (more grounded, same null conclusions)
- supplier_rev_uplift_pct: X=0 vs Y=null -> used 0 because no supplier-side claim exists, so supplier uplift is genuinely zero, not unsizable
- confidence: X=3 vs Y=2 -> used 2 (more conservative)
| Field | Opus 4.8 | GPT-5.5 |
|---|
| Rev uplift % | – | – |
| EPS uplift % | – | – |
| Priced in | medium | medium |
| vs analysts | unclear | unclear |
| Confidence | 2 | 3 |
| Top line | Unsizable. The only quantified AI claim is a >50% lift in weight-logging frequency — an engagement signal, not revenue. Nothing in the inputs converts logging frequency to dollars (no per-user revenue delta, retention uplift, or subscriber-conversion rate disclosed), so no topline % can be honestly computed against the $2.348B base. Consensus already models 2026 revenue +23% to $2.888B; whether AI engagement contributes is not separable. | No hard topline impact is calculable. The only quantified metric is +50% weight logging frequency, but $0 of revenue base or conversion math is disclosed, so revenue uplift versus current revenue of $2.348B is null. |
| Bottom line | Unsizable. No quantified cost, headcount, or productivity saving was given — management only says efficiency benefits 'could start to emerge in 2027' and AI has the 'potential to reduce' costs. With current net income $128.4M and diluted EPS $0.51 (profitable, so an EPS-uplift % would be meaningful if anchored), there is still no figure to flow through (1-21%) tax. est_eps_uplift_pct = null. | No hard EPS impact is calculable. Cost efficiency is unquantified and expected to begin in 2027; applying the current 5.4678% margin or 21% tax rate is impossible without an incremental revenue or saving amount. |
| Reasoning | No adopter-side AI figure can be sized, so there is no AI-specific number to test against consensus. Consensus trajectory: revenue $2.349B(25) -> $2.888B(26, +23%) -> $3.441B(27, +19%); EPS $0.464 -> -$0.043 (2026 loss) -> $0.507. The 2027 EPS recovery roughly coincides with the window where management says AI efficiency 'could start to emerge,' so any benefit is plausibly already inside the 2027 rebound rather than incremental to it — but with the AI impact unquantified this is an inference, not a measured gap. | Consensus already models FY2026 revenue of $2.888B, up 22.999% from the $2.348B current base, while FY2026 net income is expected to fall from $128.365M to -$1.349M and EPS from $0.51 to -$0.042926. Because the AI claims have no calculable next-FY revenue or EPS dollars, there is no hard math showing upside or downside versus consensus. |
Rows highlighted where the two models disagreed.
QUANTIFICATIONS
weight logging frequency from proactive messaging: more than a 50% increase (Q4 FY2025, early deployments, topline)
“Early deployments of proactive messaging and weight loss have already driven more than a 50% increase in weight logging frequency, signaling an ability to improve customer commitment and engagement as they progress in their weight loss journey.”
PAST (realized)
- Q4 FY2025, Andrew Dudum: "Early deployments of proactive messaging and weight loss have already driven more than a 50% increase in weight logging frequency, signaling an ability to improve customer commitment and engagement as they progress in their weight loss journey."
- Q4 FY2025, Yemi Okupe: "We have already seen early signals as demonstrated by our ability to bring multiple specialties to market in the second half of 2025 as well as our ability to improve the customer experience and realize operational efficiencies."
- Q1 FY2026, Mohamed ElShenawy: "We've also built our AI organization from scratch."
CURRENT (now)
- Q1 FY2026, Mohamed ElShenawy: "For example, we currently have an AI copilot live on the provider side of the platform that draft contextual responses on behalf of our care coaches, which are then reviewed by the care coaches before being sent."
- Q1 FY2026, Mohamed ElShenawy: "We also recently launched Labs AI, an agent that explains biomarker results in the full unique context of each customer. Flags what matters and knows when to recommend escalation to a provider."
- Q1 FY2026, Mohamed ElShenawy: "This means we are generating clinician verified training signals for our models."
FORWARD (guidance)
- Q1 FY2026, Mohamed ElShenawy: "And soon, we will launch an AI weight loss companion that will support customers along their journey, proactively reach out at the right moment to help customers hit their desired outcomes and prompt clinician engagement when their expertise is needed."
- Q1 FY2026, Yemi Okupe: "Lastly, [indiscernible], in particular, has the potential to reduce both organizational and operational costs in a way that not only does not sacrifice service quality for subscribers, but enhances it."
- Q1 FY2026, Yemi Okupe: "Our expectation is that some of these efficiency benefits could start to emerge in 2027."
- Q4 FY2025, Andrew Dudum: "Second, AI will become a critical layer on top of that data that helps define, refine and implement precision treatments, interventions and lifestyle adjustments."
TRACK RECORD — PROMISE vs DELIVERY
55/100 track record too-early 6 calls reviewed
HIMS leans heavily on an AI/personalization narrative but rarely attaches a hard number AND date to AI specifically — its quantified targets (2030 $6.5B/$1.3B, Hers $1B in 2026, intl $1B) are platform-level revenue goals still too-early to judge. Where it described concrete AI features (provider copilot, Labs AI, proactive messaging) it shipped them and showed a measured engagement lift, giving a cautiously credible-but-unproven track record.
By 2030, generate at least $6.5B revenue and $1.3B adjusted EBITDA from the personalized, data/AI-driven healthcare roadmap — promised Q1 FY2025
too-early Reaffirmed every call through Q1 FY2026 and tracking up (FY2025 revenue $2.35B, +59%), but the 2030 milestone is years away and not yet judgeable
Hers brand to scale to over $1B in annual revenue in 2026, driven by personalization/new specialties — promised Q3 FY2025
too-early Still on pace per Q4 FY2025/Q1 FY2026, but full-year 2026 not yet reported
International business to reach more than $1B in annual revenue within ~3 years (by 2028) — promised Q4 FY2025
too-early Backed by Zava/Eucalyptus/Livewell acquisitions; timeframe has not arrived
Build AI-powered personalized agents with 24/7 always-on support across the care journey — promised Q2 FY2025
partial By Q1 FY2026 a provider-side AI copilot was live drafting care-coach responses and Labs AI shipped explaining 130+ biomarkers, but a fully realized end-to-end always-on agent is not yet realized
Proactive AI messaging to improve weight-loss engagement — promised Q2 FY2025
delivered By Q4 FY2025 reported a measured >50% increase in weight-logging frequency — a concrete delivered result on the AI capability
Expand from hundreds of personalized treatment variations to thousands over the coming years — promised Q4 FY2024
too-early Later calls reported growth to 1.6M personalized-treatment subscribers and more infrastructure, but did not confirm thousands of live treatments; multi-year window still open
PRICED-IN (REFINED)
MEDIUMEst. revisions flat · Fwd P/E 59.2 · EV/Sales 3.0x
AI claim maps to UNITED STATES, Non-US
Ratings have improved somewhat since early 2026 with fewer negative calls, but buy counts are not meaningfully migrating higher and the last-month target average is only slightly above the quarter average while still below the last-year average. Consensus revenue forecasts already embed strong growth, but EPS estimates are uneven, so revision momentum looks mixed rather than clearly rising. The valuation is rich at about 59.2x forward EPS and 3.0x EV/sales, implying some AI-driven upside is already reflected, but the lack of clear upward estimate revisions keeps the priced-in verdict at medium rather than high.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
8Q4 FY20248Q1 FY20257Q2 FY20256Q3 FY20256Q4 FY20257Q1 FY2026
AI enthusiasm across 6 calls — trend → flat
AI/data stayed central to personalization and network effects, but specificity shifted from explicit tools to broader platform and diagnostics claims.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
8/10 qualitative impact material medium-term · mixed evidence
Where AI matters: personalized care, engagement, provider workflow
AI is moving into HIMS' core care loop: provider copilots, Labs AI, proactive weight-loss engagement, and planned specialty agents could improve retention, outcomes, and care-coach/provider leverage across major lines. The upside is credible but still mostly unmonetized, with only a >50% weight-logging lift disclosed rather than revenue, margin, or retention conversion.
Caveats: No disclosed AI-specific revenue, retention, or EPS contribution; Clinical/regulatory risk if AI agents overstep or produce unsafe guidance; Provider review requirements may limit automation leverage; Competitors can adopt similar AI layers, reducing differentiation
AI DISRUPTION / CANNIBALIZATION RISK two-sided · 3/10
AI can commoditize parts of digital health coaching, lab interpretation, triage, and personalized messaging, making it easier for rivals or incumbents to match some user-experience features. The core model remains relatively durable because HIMS monetizes regulated care access, prescriptions, fulfillment, brand, and longitudinal patient data rather than selling generic advice alone.
OPTIONS / MARKET STRUCTURE
option liquidity: good
proxy inputs — dollar-ADV $932M · beta 2.423 · px $27.51
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 8/10 committed.
INSIDERS selling 14 open-market sell(s) vs 1 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 83 new / 140 closed positions; 243 increased / 143 reduced; institutional ownership -15.27pp; -65 net 13F holders
MGMT LANGUAGE 8/10 committed AI language is concrete and owned, with team size and live product deployments; only modest aspirational framing around broader healthcare impact.
commit “We've also built our AI organization from scratch.”
commit “We now have nearly 40 members in our AI team”
commit “we currently have an AI copilot live on the provider side of the platform”
VERBATIM AI QUOTES
“I'm thrilled to be back to share how we are leveraging data and AI to make ourselves an irreplaceable companion to our customers and an incredibly valuable partner to other healthy innovators who want to reach and hold on to more customers.”
— Mohamed ElShenawy, Q1 FY2026
“We've also built our AI organization from scratch. We now have nearly 40 members in our AI team, including senior AI engineers and applied scientists, PhDs, from MIT, Berkeley and other top schools and seasoned leaders from top tech companies.”
— Mohamed ElShenawy, Q1 FY2026
“Second, with embedded intelligence at every step of the care journey, while keeping independent providers responsible for all clinical decision-making.”
— Mohamed ElShenawy, Q1 FY2026
“For example, we currently have an AI copilot live on the provider side of the platform that draft contextual responses on behalf of our care coaches, which are then reviewed by the care coaches before being sent.”
— Mohamed ElShenawy, Q1 FY2026
“This isn't just an efficiency play. It's a way to increase the quality of care because it produces responses informed by the full patient context that human coaches alone could not deliver at that scale.”
— Mohamed ElShenawy, Q1 FY2026
“We also recently launched Labs AI, an agent that explains biomarker results in the full unique context of each customer. Flags what matters and knows when to recommend escalation to a provider.”
— Mohamed ElShenawy, Q1 FY2026
“And soon, we will launch an AI weight loss companion that will support customers along their journey, proactively reach out at the right moment to help customers hit their desired outcomes and prompt clinician engagement when their expertise is needed.”
— Mohamed ElShenawy, Q1 FY2026
“This means we are generating clinician verified training signals for our models. This is the highest quality label in AI any company can hope for, and it can't be acquired.”
— Mohamed ElShenawy, Q1 FY2026
“Better data sets the cycle in motion, powering smarter agents, improving care, attracting top providers to our networks and continuously deepening our clinical insight.”
— Mohamed ElShenawy, Q1 FY2026
“What we're building is a platform that can continuously expand its categories of care with an intelligent layer that personalizes every step of the customer experience and a trust architecture that earns the right to operate in health care.”
— Mohamed ElShenawy, Q1 FY2026
“The lab companion and the upcoming weight loss companion are really the first iterations in what I would expect eventually becomes multiple agents that are supporting each stage of the customers' journey across every specialty we serve.”
— Andrew Dudum, Q1 FY2026
“Lastly, [indiscernible], in particular, has the potential to reduce both organizational and operational costs in a way that not only does not sacrifice service quality for subscribers, but enhances it.”
— Yemi Okupe, Q1 FY2026
“For AI-supported readouts, highlight metrics that are already optimized and those that need attention, while also educating customers on both lifestyle and clinical interventions.”
— Andrew Dudum, Q4 FY2025
“Second, AI will become a critical layer on top of that data that helps define, refine and implement precision treatments, interventions and lifestyle adjustments.”
— Andrew Dudum, Q4 FY2025
“Early deployments of proactive messaging and weight loss have already driven more than a 50% increase in weight logging frequency, signaling an ability to improve customer commitment and engagement as they progress in their weight loss journey.”
— Andrew Dudum, Q4 FY2025
“And behind the scenes, automation is removing cumbersome processes and facilitating administrative interactions, allowing providers to focus on clinical decision-making.”
— Andrew Dudum, Q4 FY2025
“Investment in engineering and AI talent has resulted in modest deleveraging, but we believe the ROI will be substantial as a result of an ability to move faster and elevate our consumer offering.”
— Yemi Okupe, Q4 FY2025
“We expect that investments in these areas will ultimately allow us to provide users with the ability to perform blood draws from the comfort of their own home and AI technology can help orient providers toward the tests that are most impactful for a subscriber at any point in time.”
— Yemi Okupe, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Retail community): What is the long-term vision for the recently launched Labs AI health care agent, specifically where is ultimate goal or final form that Hims & Hers aims to achieve with this product?
A: Andrew Dudum: "The lab companion and the upcoming weight loss companion are really the first iterations in what I would expect eventually becomes multiple agents that are supporting each stage of the customers' journey across every specialty we serve."
Q (Q1 FY2026, Justin Patterson): Could you expand on how AI could change the user experience over time and how you're thinking about incorporating feedback loops? It does seem like there's a unique opportunity there to deepen insight into the customer and gain some more outcomes data on treatments.
A: Andrew Dudum: "As I was mentioning, I think you can see we're essentially building a multi-agent model where both consumers and providers are empowered at each step of the customer journey to optimize, personalize and ultimately drive better outcomes for the patient."
Q (Q4 FY2025, Justin Patterson): It sounds like between AI, labs and wearables, you're creating the conditions for a flywheel down the road. So I would love to hear a little bit more about just how deep you're looking to go into the wearables ecosystem?
A: Andrew Dudum: "I think those 3 buckets are a real focus for the business."
Q (Q4 FY2025, Justin Patterson): How long we should really think about the investments to support some of these initiatives and how we should think about Labs, the steps to scale up Labs over the next year or so?
A: Yemi Okupe: "Ultimately, we think that these investments as they start to come together in 2026, even outer years, have the ability to quickly have positive ROI and ultimately pay off for themselves and become self-funding."